Antifungal and antibiofilm effect of duloxetine hydrochloride against Cryptococcus neoformans and Cryptococcus gattii.
Cryptococcus spp
Biofilm
Drug repurposing
Duloxetine hydrochloride
Journal
Folia microbiologica
ISSN: 1874-9356
Titre abrégé: Folia Microbiol (Praha)
Pays: United States
ID NLM: 0376757
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
received:
24
10
2023
accepted:
05
04
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
23
4
2024
Statut:
aheadofprint
Résumé
Cryptococcosis is an invasive mycosis caused mainly by Cryptococcus gattii and C. neoformans and is treated with amphotericin B (AMB), fluconazole and 5-fluorocytosine. However, antifungal resistance, limited and toxic antifungal arsenal stimulate the search for therapeutic strategies such as drug repurposing. Among the repurposed drugs studied, the selective serotonin reuptake inhibitors (SSRIs) have shown activity against Cryptococcus spp. However, little is known about the antifungal effect of duloxetine hydrochloride (DH), a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), against C. neoformans and C. gattii. In this study, DH inhibited the growth of several C. neoformans and C. gattii strains at concentrations ranging from 15.62 to 62.50 µg/mL. In addition, DH exhibited fungicidal activity ranging from 15.62 to 250 µg/mL. In biofilm, DH treatment reduced Cryptococcus spp. biomass at a level comparable to AMB, with a significant reduction (85%) for C. neoformans biofilms. The metabolic activity of C. neoformans and C. gattii biofilms decreased significantly (99%) after treatment with DH. Scanning electron micrographs confirmed the anti-biofilm activity of DH, as isolated cells could be observed after treatment. In conclusion, DH showed promising antifungal activity against planktonic cells and biofilms of C. neoformans and C. gattii, opening perspectives for further studies with DH in vivo.
Identifiants
pubmed: 38652436
doi: 10.1007/s12223-024-01164-1
pii: 10.1007/s12223-024-01164-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i.
Références
Almeida F, Wolf JM, Casadevall A (2015) Virulence-associated enzymes of Cryptococcus neoformans. Eukaryot Cell 14(12):1173–1185. https://doi.org/10.1128/EC.00103-15
doi: 10.1128/EC.00103-15
pubmed: 26453651
pmcid: 4664877
Almeida-Paes R, Frases S (2023) Repurposing drugs for fungal infections: advantages and limitations. Future Microbiol. https://doi.org/10.2217/fmb-2023-0108
doi: 10.2217/fmb-2023-0108
pubmed: 37721517
Alves V, Martins PH, Miranda B, de Andrade IB, Pereira L, Maeda CT, de Sousa Araújo GR, Frases S (2023) Assessing the in vitro potential of glatiramer acetate (copaxone
doi: 10.3390/jof9080783
Arendrup MC, Meletiadis J, Mouton JW, Lagrou K, Hamal P, Guinea J, AFST/ESCMID/EUCAST (2017) EUCAST DEFINITIVE DOCUMENT E.DEF 7.3.1. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. 1–21. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_7_3_1_Yeast_testing__definitive.pdf
Barbosa JO, Rossoni RD, Vilela SFG, De Alvarenga JA, Velloso MDS, Prata MCDA, Jorge AOC, Junqueira JC (2016) Streptococcus mutans can modulate biofilm formation and attenuate the virulence of Candida albicans. PLoS ONE 11(3):e0150457. https://doi.org/10.1371/journal.pone.0150457
doi: 10.1371/journal.pone.0150457
pubmed: 26934196
pmcid: 4774980
Borrelli F, Izzo AA (2009) Herb–drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 11:710–727. https://doi.org/10.1208/s12248-009-9146-8
doi: 10.1208/s12248-009-9146-8
pubmed: 19859815
pmcid: 2782080
Cassetta MI, Marzo T, Fallani S, Novelli A, Messori L (2014) Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 27(4):787–791. https://doi.org/10.1007/s10534-014-9743-6
doi: 10.1007/s10534-014-9743-6
pubmed: 24820140
Chastain DB, Kung VM, Vargas Barahona L, Jackson BT, Golpayegany S, Franco-Paredes C, Thompson GR, Henao-Martínez AF (2022) Characteristics and outcomes of cryptococcosis among patients with and without COVID-19. J Fungi 8(11):1234. https://doi.org/10.3390/jof8111234
doi: 10.3390/jof8111234
Chen T, Mwenge L, Lakhi S, Chanda D, Mwaba P, Molloy SF, Gheorghe A, Griffiths UK, Heyderman RS, Kanyama C, Kouanfack C, Mfinanga S, Chan AK, Temfack E, Kivuyo S, Hosseinipour MC, Lortholary O, Loyse A, Jaffar S, Niessen LW (2019) Healthcare costs and life-years gained from treatments within the advancing cryptococcal meningitis treatment for africa (ACTA) trial on cryptococcal meningitis: a comparison of antifungal induction strategies in sub-saharan africa. Clin Infect Dis 69(4):588–595. https://doi.org/10.1093/cid/ciy971
doi: 10.1093/cid/ciy971
pubmed: 30863852
pmcid: 6669289
Costa Silva RA, da Silva CR, de Andrade Neto JB, da Silva AR, Campos RS, Sampaio LS, do Nascimento FBSA, da Silva Gaspar B, da Cruz Fonseca SG, Josino MAA, Grangeiro TB, Gaspar DM, de Lucena DF, de Moraes MO, Cavalcanti BC, Nobre Júnior HV (2017) In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates. Microb Pathog 107:341–348. https://doi.org/10.1016/j.micpath.2017.04.008
doi: 10.1016/j.micpath.2017.04.008
pubmed: 28411060
da Silva CR, do Amaral Valente Sá LG, Ferreira TL, Leitão AC, de Farias Cabral VP, Rodrigues DS, Barbosa AD, Moreira LEA, Filho HLP, de Andrade Neto JB, Rios MEF, Cavalcanti BC, Magalhães HIF, de Moraes MO, Nobre HV (2023) Antifungal activity of selective serotonin reuptake inhibitors against Cryptococcus spp and their possible mechanism of action. J Med Mycol 33(4):101431. https://doi.org/10.1016/j.mycmed.2023.101431
doi: 10.1016/j.mycmed.2023.101431
Deng H, Song J, Huang Y, Yang C, Zang X, Zhou Y, Li H, Dai B, Xue X (2023) Combating increased antifungal drug resistance in Cryptococcus, what should we do in the future? Acta Biochim Biophys Sin 55(4):540–547. https://doi.org/10.3724/abbs.2023011
doi: 10.3724/abbs.2023011
pubmed: 36815374
pmcid: 10195138
Feng X, Fu X, Ling B, Wang L, Liao W, Yao Z (2013) Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var. grubii, Cryptococcus neoformans var. neoformans, Cryptococcus gattii, and hybrids. J Clin Microbiol 51(6):1920–1923. https://doi.org/10.1128/JCM.00064-13
doi: 10.1128/JCM.00064-13
pubmed: 23536400
pmcid: 3716086
Freitas GJC, Ribeiro NQ, Gouveia-Eufrasio L, Emidio ECP, Guimarães GM, César IC, Paixão TA, Oliveira JBS, Caza M, Kronstad JW, Santos DA (2023) Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis. Int J Antimicrob Agents 62(1):106807. https://doi.org/10.1016/j.ijantimicag.2023.106807
doi: 10.1016/j.ijantimicag.2023.106807
pubmed: 37030471
Hazen KC (1998) Fungicidal versus fungistatic activity of terbinafine and itraconazole: An in vitro comparison. J Am Acad Dermatol 38(5):S37–S44. https://doi.org/10.1016/S0190-9622(98)70482-7
doi: 10.1016/S0190-9622(98)70482-7
pubmed: 9594935
Kane A, Carter DA (2022) Augmenting azoles with drug synergy to expand the antifungal toolbox. Pharmaceuticals 15(4):482. https://doi.org/10.3390/ph15040482
doi: 10.3390/ph15040482
pubmed: 35455479
pmcid: 9027798
Katende A, Mbwanji G, Faini D, Nyuri A, Kalinjuma AV, Mnzava D, Hullsiek KH, Rhein J, Weisser M, Meya DB, Boulware DR, Letang E (2019) Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. Mycoses 62(12):1127–1132. https://doi.org/10.1111/myc.12995
doi: 10.1111/myc.12995
pubmed: 31461550
pmcid: 6834866
Laniado-Laborín R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26(4):223–227. https://doi.org/10.1016/j.riam.2009.06.003
doi: 10.1016/j.riam.2009.06.003
pubmed: 19836985
Martinez LR, Casadevall A (2006) Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 50(3):1021–1033. https://doi.org/10.1128/AAC.50.3.1021-1033.2006
doi: 10.1128/AAC.50.3.1021-1033.2006
pubmed: 16495265
pmcid: 1426450
Martinez LR, Casadevall A (2015) Biofilm formation by Cryptococcus neoformans. Microbiol Spectr 3(3). https://doi.org/10.1128/microbiolspec.MB-0006-2014
Menezes RT, Pereira TC, Junqueira JC, Oliveira LD, Scorzoni L (2022) Synergistic combination of duloxetine hydrochloride and fluconazole reduces the cell growth and capsule size of Cryptococcus neoformans. Anais Da Academia Brasileira de Ciências 94(2):e20211021. https://doi.org/10.1590/0001-3765202220211021
doi: 10.1590/0001-3765202220211021
pubmed: 35544847
Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discovery 8(12):959–968. https://doi.org/10.1038/nrd2961
doi: 10.1038/nrd2961
pubmed: 19949401
Nochaiwong S, Ruengorn C, Awiphan R, Chai-Adisaksopha C, Tantraworasin A, Phosuya C, Kanjanarat P, Chongruksut W, Sood MM, Thavorn K (2022) Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med 54(1):80–97. https://doi.org/10.1080/07853890.2021.2017474
doi: 10.1080/07853890.2021.2017474
pubmed: 34955074
Oprea TI, Mestres J (2012) Drug repurposing: far beyond new targets for old drugs. AAPS J 14(4):759–763. https://doi.org/10.1208/s12248-012-9390-1
doi: 10.1208/s12248-012-9390-1
pubmed: 22826034
pmcid: 3475856
Paulzen M, Gründer G, Veselinovic T, Wolf B, Hiemke C, Lammertz SE (2016) Duloxetine enters the brain–But why is it not found in the cerebrospinal fluid. J Affect Disord 189:159–163. https://doi.org/10.1016/j.jad.2015.08.073
doi: 10.1016/j.jad.2015.08.073
pubmed: 26437230
Peeters E, Nelis HJ, Coenye T (2008) Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 72(2):157–165. https://doi.org/10.1016/j.mimet.2007.11.010
doi: 10.1016/j.mimet.2007.11.010
pubmed: 18155789
Pereira TC, De Menezes RT, De Oliveira HC, De Oliveira LD, Scorzoni L (2021) In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans. Pathog Dis 79(2):ftab001. https://doi.org/10.1093/femspd/ftab001
doi: 10.1093/femspd/ftab001
pubmed: 33417701
Periyasami G, Karuppiah P, Karthikeyan P, Palaniappan S (2023) Anti-infective efficacy of duloxetine against catheter-associated urinary tract infections caused by gram-positive bacteria. ACS Ômega 8(50):48317–48325. https://doi.org/10.1021/acsomega.3c07676
doi: 10.1021/acsomega.3c07676
pubmed: 38144107
pmcid: 10734014
Preskorn SH (2004) Duloxetine. J Psychiatr Pract 10(6):375–385. https://doi.org/10.1097/00131746-200411000-00006
doi: 10.1097/00131746-200411000-00006
pubmed: 15583519
Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, Denning DW, Meya DB, Chiller TM, Boulware DR (2022) The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis 22(12):1748–1755. https://doi.org/10.1016/S1473-3099(22)00499-6
doi: 10.1016/S1473-3099(22)00499-6
pubmed: 36049486
pmcid: 9701154
Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2008) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104(4):289–298. https://doi.org/10.1111/j.1600-0447.2001.00263.x
doi: 10.1111/j.1600-0447.2001.00263.x
Rathore SS, Sathiyamoorthy J, Lalitha C, Ramakrishnan J (2022) A holistic review on Cryptococcus neoformans. Microb Pathog 166:105521. https://doi.org/10.1016/j.micpath.2022.105521
doi: 10.1016/j.micpath.2022.105521
pubmed: 35436563
Ribeiro NQ, Santos APN, Emídio ECP, Costa MC, Freitas GJC, Carmo PHF, Silva MF, de Brito CB, de Souza DG, Paixão TA, Santos DA (2019) Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. Int J Antimicrob Agents 54(3):301–308. https://doi.org/10.1016/j.ijantimicag.2019.06.020
doi: 10.1016/j.ijantimicag.2019.06.020
pubmed: 31279153
Rizea-Savu S, Duna SN, Ghita A, Iordachescu A, Chirila M (2020) The effect of food on the single-dose bioavailability and tolerability of the highest marketed strength of duloxetine. Clin Pharmacol Drug Dev 9(7):797–804. https://doi.org/10.1002/cpdd.759
doi: 10.1002/cpdd.759
pubmed: 31793229
Rodrigues DS, Cabral VPF, Barbosa AD, Sá LGDAV, Moreira LEA, de Andrade Neto JB, da Silva CR, de Moraes MO, Silva J, Marinho ES, Dos Santos HS, da Costa ÉRM, Silveira MJCB, E Silva LH, Nobre Júnior HV (2023) Sertraline has in vitro activity against both mature and forming biofilms of different Candida species. J Med Microbiol 72(2). https://doi.org/10.1099/jmm.0.001664 . PMID: 36762524
Rossato L, Loreto ÉS, Zanette RA, Chassot F, Santurio JM, Alves SH (2016) In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii. Folia Microbiologica 61(5):399–403. https://doi.org/10.1007/s12223-016-0449-8
doi: 10.1007/s12223-016-0449-8
pubmed: 26847460
Salem HF, Ali AA, Rabea YK, El-Ela FIA, Khallaf RA (2022) Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal. Drug Deliv Transl Res 12(12):3083–3103. https://doi.org/10.1007/s13346-022-01172-z
doi: 10.1007/s13346-022-01172-z
pubmed: 35622235
pmcid: 9636110
Spandana KA, Bhaskaran M, Karri VR, Natarajan J (2020) A comprehensive review of nano drug delivery system in the treatment of CNS disorders. J Drug Deliv Sci Technol 57:101628. https://doi.org/10.1016/j.jddst.2020.101628
doi: 10.1016/j.jddst.2020.101628
Treviño-Rangel RDJ, Villanueva-Lozano H, Hernández-Rodríguez P, Martínez-Reséndez MF, García-Juárez J, Rodríguez-Rocha H, González GM (2016) Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays. Med Mycol 54(3):280–286. https://doi.org/10.1093/mmy/myv109
doi: 10.1093/mmy/myv109
pubmed: 26705833
Vey EL, Kovelman I (2010) Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey. J Forensic Leg Med 17(4):175–185. https://doi.org/10.1016/j.jflm.2010.02.002
doi: 10.1016/j.jflm.2010.02.002
pubmed: 20382351
Waitekus AB, Kirkpatrick P (2004) Duloxetine hydrochloride. Nat Rev Drug Discov 3(11):907–908. https://doi.org/10.1038/nrd1555
doi: 10.1038/nrd1555
pubmed: 15558861
Wang Y, Pawar S, Dutta O, Wang K, Rivera A, Xue C (2022) Macrophage mediated immunomodulation during cryptococcus pulmonary infection. Front Cell Infect Microbiol. https://doi.org/10.3389/fcimb.2022.859049
doi: 10.3389/fcimb.2022.859049
pubmed: 37056463
pmcid: 9831678
Zhai B, Wu C, Wang L, Sachs MS, Lin X (2012) The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 56(7):3758–3766. https://doi.org/10.1128/AAC.00212-12
doi: 10.1128/AAC.00212-12
pubmed: 22508310
pmcid: 3393448